4 results match your criteria Annals of pancreatic cancer[Journal]

  • Page 1 of 1

Adjuvant therapeutic strategies for resectable pancreatic adenocarcinoma.

Ann Pancreat Cancer 2018 Aug 6;1. Epub 2018 Aug 6.

Department of Radiation Oncology, Rutgers Cancer Institute of New Jersey, Rutgers Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.

Of all patients diagnosed with pancreatic adenocarcinoma, only 15-20% present with resectable disease. Despite curative-intent resection, the prognosis remains poor with the majority of patients recurring, prompting the need for adjuvant therapy. Historical data support the use of adjuvant 5-fluorouracil (5-FU) or gemcitabine, but recent data suggest either gemcitabine plus capecitabine or modified FOLFIRINOX can improve overall survival when compared to gemcitabine alone. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2018.07.05DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6345263PMC
August 2018
4 Reads

Immune defects in pancreatic cancer.

Authors:
Lei Zheng

Ann Pancreat Cancer 2018 Dec 6;1. Epub 2018 Dec 6.

The Pancreatic Cancer Precision Medicine Center of Excellence Program, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

Pancreatic cancer is resistant to the immunotherapy. This resistance is caused by any of the four immune "defects" that occur in pancreatic cancer, including lack of "high quality" T cells, stromal barriers to T cells getting access to tumor cells, immunosuppressive cells such as M2 macrophages, myeloid derivative suppressor cells, and T regulatory cells, in the tumor microenvironment of pancreatic cancer. One or more defects may occur in an individual pancreatic cancer. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2018.11.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6319882PMC
December 2018
8 Reads

Current and emerging radiotherapy strategies for pancreatic adenocarcinoma: stereotactic, intensity modulated and particle radiotherapy.

Ann Pancreat Cancer 2018 Aug 13;1. Epub 2018 Aug 13.

Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

The role of radiotherapy for locally advanced pancreatic cancer (LAPC) is unclear based on studies that used conventional doses and fractionation schedules. Modern radiotherapy techniques have not been studied in depth, however. We reviewed the literature on emerging methods of delivering higher doses of conformal radiotherapy using stereotactic body radiation, intensity modulated radiation, and particle beam radiation, highlighting clinical outcomes and toxicities. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/apc.2018.07.03DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6124686PMC
August 2018
1 Read

Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis.

Ann Pancreat Cancer 2018 27;1. Epub 2018 Feb 27.

Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.

Background: Pancreatic ductal adenocarcinoma (PDAC) often presents with nonspecific symptoms and the workup is not standardized. To study the impact of delays in diagnosis and in the initiation of treatment, we investigated the relationship between length of diagnostic intervals and surgical resectability.

Methods: We performed a retrospective chart review of patients evaluated for PDAC at Johns Hopkins in 2014. Read More

View Article

Download full-text PDF

Source
http://apc.amegroups.com/article/view/4014/4720
Publisher Site
http://dx.doi.org/10.21037/apc.2018.02.01DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909699PMC
February 2018
9 Reads
  • Page 1 of 1